Preprint describing NRCAM, a new pediatric high-grade glioma neoepitope online!

As a part of our splice-derived neoepitope identification research, we partnered with Dr. Andrei Thomas-Tikhonenko’s laboratory at Children’s Hospital of Philadelphia in which they validated an NRCAM splice event as a targetable immunotherapeutic target for pediatric high-grade gliomas. Please read more in “Neuronal cell adhesion molecule (NRCAM) variant defined by microexon skipping is an essential, antigenically distinct, and targetable proteoform in high-grade glioma” here.